NDC 25021-231 Decitabine

Decitabine

NDC Product Code 25021-231

NDC CODE: 25021-231

Proprietary Name: Decitabine What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Decitabine What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This medication is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS may have problems such as infections, anemia, and easy bleeding/bruising. Decitabine is a chemotherapy drug. It is believed to work by helping your bone marrow grow normal blood cells so you will need fewer blood transfusions. Decitabine also kills abnormal blood cells that have grown too fast and do not work properly.

NDC Code Structure

  • 25021 - Sagent Pharmaceuticals

NDC 25021-231-20

Package Description: 1 VIAL in 1 CARTON > 20 mL in 1 VIAL

NDC Product Information

Decitabine with NDC 25021-231 is a a human prescription drug product labeled by Sagent Pharmaceuticals. The generic name of Decitabine is decitabine. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intravenous form.

Labeler Name: Sagent Pharmaceuticals

Dosage Form: Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Decitabine Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DECITABINE 50 mg/20mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • POTASSIUM PHOSPHATE, MONOBASIC (UNII: 4J9FJ0HL51)
  • SODIUM HYDROXIDE (UNII: 55X04QC32I)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Nucleic Acid Synthesis Inhibitors - [MoA] (Mechanism of Action)
  • Nucleoside Metabolic Inhibitor - [EPC] (Established Pharmacologic Class)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Sagent Pharmaceuticals
Labeler Code: 25021
FDA Application Number: ANDA207100 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 08-15-2018 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2022 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients

Decitabine Injection

Decitabine Injection is pronounced as (dee sye' ta been)

Why is decitabine injection medication prescribed?
Decitabine is used to treat myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough h...
[Read More]

* Please review the disclaimer below.

Decitabine Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

Decitabine for Injection is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

2 Dosage And Administration

There are two regimens for decitabine for injection administration. With either regimen it is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial response may take longer than 4 cycles.
Complete blood counts and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each cycle. Liver chemistries and serum creatinine should be obtained prior to initiation of treatment.

2.1 Treatment Regimen – Option 1

  • Decitabine for injection is administered at a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days. This cycle should be repeated every 6 weeks. Patients may be premedicated with standard anti-emetic therapy.
  • If hematologic recovery (ANC ≥ 1,000/μL and platelets ≥ 50,000/μL) from a previous decitabine for injection treatment cycle requires more than 6 weeks, then the next cycle of decitabine for injection therapy should be delayed and dosing temporarily reduced by following this algorithm:
  • Recovery requiring more than 6, but less than 8 weeks – Decitabine for injection dosing to be delayed for up to 2 weeks and the dose temporarily reduced to 11 mg/m2 every 8 hours (33 mg/m2/day, 99 mg/m2/cycle) upon restarting therapy.
  • Recovery requiring more than 8, but less than 10 weeks − Patient should be assessed for disease progression (by bone marrow aspirates); in the absence of progression, the decitabine for injection dose should be delayed up to 2 more weeks and the dose reduced to 11 mg/m2 every 8 hours (33 mg/m2/day, 99 mg/m2/cycle) upon restarting therapy, then maintained or increased in subsequent cycles as clinically indicated.

2.2 Treatment Regimen – Option 2

Decitabine for injection is administered at a dose of 20 mg/m2 by continuous intravenous infusion over 1 hour repeated daily for 5 days. This cycle should be repeated every 4 weeks. Patients may be premedicated with standard anti-emetic therapy.
If myelosuppression is present, subsequent treatment cycles of decitabine for injection should be delayed until there is hematologic recovery (ANC ≥ 1,000/μL platelets ≥ 50,000/μL).

2.3 Patients With Non-Hematologic Toxicity

Following the first cycle of decitabine for injection treatment, if any of the following non-hematologic toxicities are present, decitabine for injection treatment should not be restarted until the toxicity is resolved: 1) serum creatinine ≥ 2 mg/dL; 2) SGPT, total bilirubin ≥ 2 times ULN; 3) and active or uncontrolled infection.

2.4 Instructions For Intravenous Administration

Decitabine for injection is a cytotoxic drug and caution should be exercised when handling and preparing decitabine for injection. Procedures for proper handling and disposal of antineoplastic drugs should be applied. Several guidances on this subject have been published1-4.
Decitabine for injection should be aseptically reconstituted with 10 mL of Sterile Water for Injection (USP); upon reconstitution, each mL contains approximately 5 mg of decitabine at pH 6.7 to 7.3. Immediately after reconstitution, the solution should be further diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a final drug concentration of 0.1 to 1 mg per mL. Unless used within 15 minutes of reconstitution, the diluted solution must be prepared using cold (2˚C to 8˚C) infusion fluids and stored between 2˚ and 8˚C (36˚ and 46˚F) for up to a maximum of 4 hours until administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if there is evidence of particulate matter or discoloration.

3 Dosage Forms And Strengths

Decitabine for Injection is supplied as a sterile, lyophilized white to almost white powder, in a single-dose vial, packaged in cartons of 1 vial. Each vial contains 50 mg of decitabine.

4 Contraindications

None

5.1 Neutropenia And Thrombocytopenia

Treatment with decitabine is associated with neutropenia and thrombocytopenia. Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle. After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted [see Dosage and Administration (2.1, 2.2)]. Clinicians should consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with MDS. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles, and may not necessarily indicate progression of underlying MDS.

5.2 Use In Pregnancy

Decitabine can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action, decitabine is expected to result in adverse reproductive effects. In preclinical studies in mice and rats, decitabine was teratogenic, fetotoxic, and embryotoxic. There are no adequate and well-controlled studies of decitabine in pregnant women. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while taking decitabine [see Use in Specific Populations (8.1)]

5.3 Use In Women Of Childbearing Potential

Women of childbearing potential should be advised to avoid becoming pregnant while receiving decitabine and for 1 month following completion of treatment. Women of childbearing potential should be counseled to use effective contraception during this time [see Use in Specific Populations (8.1)]. Based on its mechanism of action, decitabine can cause fetal harm if used during pregnancy.

5.4 Use In Men

Men should be advised not to father a child while receiving treatment with decitabine, and for 2 months following completion of treatment [see Nonclinical Toxicology (13.1)]. Men with female partners of childbearing potential should use effective contraception during this time. Based on its mechanism of action, decitabine alters DNA synthesis and can cause fetal harm.

6.1 Clinical Studies Experience

  • Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
  • Most Commonly Occurring Adverse Reactions: neutropenia, thrombocytopenia, anemia, fatigue, pyrexia, nausea, cough, petechiae, constipation, diarrhea, and hyperglycemia.
  • Adverse Reactions Most Frequently (≥ 1%) Resulting in Clinical Intervention in the Phase 3 Trial in the Decitabine Arm:Discontinuation: thrombocytopenia, neutropenia, pneumonia, Mycobacterium avium complex infection, cardio-respiratory arrest, increased blood bilirubin, intracranial hemorrhage, abnormal liver function tests.
  • Dose Delayed: neutropenia, pulmonary edema, atrial fibrillation, central line infection, febrile neutropenia.
  • Dose Reduced: neutropenia, thrombocytopenia, anemia, lethargy, edema, tachycardia, depression, pharyngitis.
  • Discussion of Adverse Reactions InformationDecitabine was studied in 3 single-arm studies (N = 66, N = 98, N = 99) and 1 controlled supportive care study (N = 83 decitabine, N = 81 supportive care). The data described below reflect exposure to decitabine in 83 patients in the MDS trial. In the trial, patients received 15 mg/m2 intravenously every 8 hours for 3 days every 6 weeks. The median number of decitabine cycles was 3 (range 0 to 9).
  • Table 1 presents all adverse events regardless of causality occurring in at least 5% of patients in the decitabine group and at a rate greater than supportive care.
  • Table 1 Adverse Events Reported in ≥ 5% of Patients in the Decitabine Group and at a Rate Greater than Supportive Care in Phase 3 MDS Trial
  • DecitabineN = 83 (%)Supportive CareN = 81 (%)Blood and lymphatic system disorders     Neutropenia
  • 75 (90)
  • 58 (72)
  • Thrombocytopenia
  • 74 (89)
  • 64 (79)
  • Anemia NOS
  • 68 (82)
  • 60 (74)
  • Febrile neutropenia
  • 24 (29)
  • 5 (6)
  • Leukopenia NOS
  • 23 (28)
  • 11 (14)
  • Lymphadenopathy
  • 10 (12)
  • 6 (7)
  • Thrombocythemia
  • 4 (5)
  • 1 (1)
  • Cardiac disorders     Pulmonary edema NOS
  • 5 (6)
  • 0 (0)
  • Eye disorders     Vision blurred
  • 5 (6)
  • 0 (0)
  • Gastrointestinal disorders     Nausea
  • 35 (42)
  • 13 (16)
  • Constipation
  • 29 (35)
  • 11 (14)
  • Diarrhea NOS
  • 28 (34)
  • 13 (16)
  • Vomiting NOS
  • 21 (25)
  • 7 (9)
  • Abdominal pain NOS
  • 12 (14)
  • 5 (6)
  • Oral mucosal petechiae
  • 11 (13)
  • 4 (5)
  • Stomatitis
  • 10 (12)
  • 5 (6)
  • Dyspepsia
  • 10 (12)
  • 1 (1)
  • Ascites
  • 8 (10)
  • 2 (2)
  • Gingival bleeding
  • 7 (8)
  • 5 (6)
  • Hemorrhoids
  • 7 (8)
  • 3 (4)
  • Loose stools
  • 6 (7)
  • 3 (4)
  • Tongue ulceration
  • 6 (7)
  • 2 (2)
  • Dysphagia
  • 5 (6)
  • 2 (2)
  • Oral soft tissue disorder NOS
  • 5 (6)
  • 1 (1)
  • Lip ulceration
  • 4 (5)
  • 3 (4)
  • Abdominal distension
  • 4 (5)
  • 1 (1)
  • Abdominal pain upper
  • 4 (5)
  • 1 (1)
  • Gastro-esophageal reflux disease
  • 4 (5)
  • 0 (0)
  • Glossodynia
  • 4 (5)
  • 0 (0)
  • General disorders and administrative site disorders     Pyrexia
  • 44 (53)
  • 23 (28)
  • Edema peripheral
  • 21 (25)
  • 13 (16)
  • Rigors
  • 18 (22)
  • 14 (17)
  • Edema NOS
  • 15 (18)
  • 5 (6)
  • Pain NOS
  • 11 (13)
  • 5 (6)
  • Lethargy
  • 10 (12)
  • 3 (4)
  • Tenderness NOS
  • 9 (11)
  • 0 (0)
  • Fall
  • 7 (8)
  • 3 (4)
  • Chest discomfort
  • 6 (7)
  • 3 (4)
  • Intermittent pyrexia
  • 5 (6)
  • 3 (4)
  • Malaise
  • 4 (5)
  • 1 (1)
  • Crepitations NOS
  • 4 (5)
  • 1 (1)
  • Catheter site erythema
  • 4 (5)
  • 1 (1)
  • Catheter site pain
  • 4 (5)
  • 0 (0)
  • Injection site swelling
  • 4 (5)
  • 0 (0)
  • Hepatobiliary Disorders     Hyperbilirubinemia
  • 12 (14)
  • 4 (5)
  • Infections and Infestations     Pneumonia NOS
  • 18 (22)
  • 11 (14)
  • Cellulitis
  • 10 (12)
  • 6 (7)
  • Candidal infection NOS
  • 8 (10)
  • 1 (1)
  • Catheter related infection
  • 7 (8)
  • 0 (0)
  • Urinary tract infection NOS
  • 6 (7)
  • 1 (1)
  • Staphylococcal infection
  • 6 (7)
  • 0 (0)
  • Oral candidiasis
  • 5 (6)
  • 2 (2)
  • Sinusitis NOS
  • 4 (5)
  • 2 (2)
  • Bacteremia
  • 4 (5)
  • 0 (0)
  • Injury, poisoning and procedural complications     Transfusion reaction
  • 6 (7)
  • 3 (4)
  • Abrasion NOS
  • 4 (5)
  • 1 (1)
  • Investigations     Cardiac murmur NOS
  • 13 (16)
  • 9 (11)
  • Blood alkaline phosphatase NOS increased
  • 9 (11)
  • 7 (9)
  • Aspartate aminotransferase increased
  • 8 (10)
  • 7 (9)
  • Blood urea increased
  • 8 (10)
  • 1 (1)
  • Blood lactate dehydrogenase increased
  • 7 (8)
  • 5 (6)
  • Blood albumin decreased
  • 6 (7)
  • 0 (0)
  • Blood bicarbonate increased
  • 5 (6)
  • 1 (1)
  • Blood chloride decreased
  • 5 (6)
  • 1 (1)
  • Protein total decreased
  • 4 (5)
  • 3 (4)
  • Blood bicarbonate decreased
  • 4 (5)
  • 1 (1)
  • Blood bilirubin decreased
  • 4 (5)
  • 1 (1)
  • Metabolism and nutrition disorders     Hyperglycemia NOS
  • 27 (33)
  • 16 (20)
  • Hypoalbuminemia
  • 20 (24)
  • 14 (17)
  • Hypomagnesemia
  • 20 (24)
  • 6 (7)
  • Hypokalemia
  • 18 (22)
  • 10 (12)
  • Hyponatremia
  • 16 (19)
  • 13 (16)
  • Appetite decreased NOS
  • 13 (16)
  • 12 (15)
  • Anorexia
  • 13 (16)
  • 8 (10)
  • Hyperkalemia
  • 11 (13)
  • 3 (4)
  • Dehydration
  • 5 (6)
  • 4 (5)
  • Musculoskeletal and connective tissue disorders     Arthralgia
  • 17 (20)
  • 8 (10)
  • Pain in limb
  • 16 (19)
  • 8 (10)
  • Back pain
  • 14 (17)
  • 5 (6)
  • Chest wall pain
  • 6 (7)
  • 1 (1)
  • Musculoskeletal discomfort
  • 5 (6)
  • 0 (0)
  • Myalgia
  • 4 (5)
  • 1 (1)
  • Nervous system disorders     Headache
  • 23 (28)
  • 11 (14)
  • Dizziness
  • 15 (18)
  • 10 (12)
  • Hypoesthesia
  • 9 (11)
  • 1 (1)
  • Psychiatric disorders     Insomnia
  • 23 (28)
  • 11 (14)
  • Confusional state
  • 10 (12)
  • 3 (4)
  • Anxiety
  • 9 (11)
  • 8 (10)
  • Renal and urinary disorders     Dysuria
  • 5 (6)
  • 3 (4)
  • Urinary frequency
  • 4 (5)
  • 1 (1)
  • Respiratory, thoracic and Mediastinal disorders     Cough
  • 33 (40)
  • 25 (31)
  • Pharyngitis
  • 13 (16)
  • 6 (7)
  • Crackles lung
  • 12 (14)
  • 1 (1)
  • Breath sounds decreased
  • 8 (10)
  • 7 (9)
  • Hypoxia
  • 8 (10)
  • 4 (5)
  • Rales
  • 7 (8)
  • 2 (2)
  • Postnasal drip
  • 4 (5)
  • 2 (2)
  • Skin and subcutaneous tissue disorders     Ecchymosis
  • 18 (22)
  • 12 (15)
  • Rash NOS
  • 16 (19)
  • 7 (9)
  • Erythema
  • 12 (14)
  • 5 (6)
  • Skin lesion NOS
  • 9 (11)
  • 3 (4)
  • Pruritis
  • 9 (11)
  • 2 (2)
  • Alopecia
  • 7 (8)
  • 1 (1)
  • Urticaria NOS
  • 5 (6)
  • 1 (1)
  • Swelling face
  • 5 (6)
  • 0 (0)
  • Vascular disorders     Petechiae
  • 32 (39)
  • 13 (16)
  • Pallor
  • 19 (23)
  • 10 (12)
  • Hypotension NOS
  • 5 (6)
  • 4 (5)
  • Hematoma NOS
  • 4 (5)
  • 3 (4)

Other

Discussion of Clinically Important Adverse ReactionsIn the controlled trial using decitabine dosed at 15 mg/m2, administered by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days, the highest incidence of Grade 3 or Grade 4 adverse events in the decitabine arm were neutropenia (87%), thrombocytopenia (85%), febrile neutropenia (23%) and leukopenia (22%). Bone marrow suppression was the most frequent cause of dose reduction, delay and discontinuation. Six patients had fatal events associated with their underlying disease and myelosuppression (anemia, neutropenia, and thrombocytopenia) that were considered at least possibly related to drug treatment [see Warnings and Precautions (5.1)]. Of the 83 decitabine-treated patients, 8 permanently discontinued therapy for adverse events; compared to 1 of 81 patients in the supportive care arm.
In a single-arm study (N=99) decitabine was dosed at 20 mg/m2 intravenous, infused over one hour daily for 5 consecutive days of a 4 week cycle. Table 2 presents all adverse events regardless of causality occurring in at least 5% of patients.
Table 2 Adverse Events Reported in ≥ 5% of Patients in a Single-arm Study*
* In this single arm study, investigators reported adverse events based on clinical signs and symptoms rather than predefined laboratory abnormalities. Thus not all laboratory abnormalities were recorded as adverse events.
DecitabineN = 99 (%)Blood and lymphatic system disorders     Anemia
31 (31%)
     Febrile neutropenia
20 (20%)
     Leukopenia
6 (6%)
     Neutropenia
38 (38%)
     Pancytopenia
5 (5%)
     Thrombocythemia
5 (5%)
     Thrombocytopenia
27 (27%)
Cardiac disorders     Cardiac failure congestive
5 (5%)
     Tachycardia
8 (8%)
Ear and labyrinth disorders     Ear pain
6 (6%)
Gastrointestinal disorders     Abdominal pain
14 (14%)
     Abdominal pain upper
6 (6%)
     Constipation
30 (30%)
     Diarrhea
28 (28%)
     Dyspepsia
10 (10%)
     Dysphagia
5 (5%)
     Gastro-esophageal reflux disease
5 (5%)
     Nausea
40 (40%)
     Oral pain
5 (5%)
     Stomatitis
11 (11%)
     Toothache
6 (6%)
     Vomiting
16 (16%)
General disorders and administration site conditions     Asthenia
15 (15%)
     Chest pain
6 (6%)
     Chills
16 (16%)
     Fatigue
46 (46%)
     Mucosal inflammation
9 (9%)
     Edema
5 (5%)
     Edema peripheral
27 (27%)
     Pain
5 (5%)
     Pyrexia
36 (36%)
Infections and infestations     Cellulitis
9 (9%)
     Oral candidiasis
6 (6%)
     Pneumonia
20 (20%)
     Sinusitis
6 (6%)
     Staphylococcal bacteremia
8 (8%)
     Tooth abscess
5 (5%)
     Upper respiratory tract infection
10 (10%)
     Urinary tract infection
7 (7%)
Injury, poisoning and procedural complications     Contusion
9 (9%)
Investigations     Blood bilirubin increased
6 (6%)
     Breath sounds abnormal
5 (5%)
     Weight decreased
9 (9%)
Metabolism and nutrition disorders     Anorexia
23 (23%)
     Decreased appetite
8 (8%)
     Dehydration
8 (8%)
     Hyperglycemia
6 (6%)
     Hypokalemia
12 (12%)
     Hypomagnesemia
5 (5%)
Musculoskeletal and connective tissue disorders     Arthralgia
17 (17%)
     Back pain
18 (18%)
     Bone pain
6 (6%)
     Muscle spasms
7 (7%)
     Muscular weakness
5 (5%)
     Musculoskeletal pain
5 (5%)
     Myalgia
9 (9%)
     Pain in extremity
18 (18%)
Nervous system disorders     Dizziness
21 (21%)
     Headache
23 (23%)
Psychiatric disorders     Anxiety
9 (9%)
     Confusional state
8 (8%)
     Depression
9 (9%)
     Insomnia
14 (14%)
Respiratory, thoracic and mediastinal disorders     Cough
27 (27%)
     Dyspnea
29 (29%)
     Epistaxis
13 (13%)
     Pharyngolaryngeal pain
8 (8%)
     Pleural effusion
5 (5%)
     Sinus congestion
5 (5%)
Skin and subcutaneous tissue disorders     Dry skin
8 (8%)
     Ecchymosis
9 (9%)
     Erythema
5 (5%)
     Night sweats
5 (5%)
     Petechiae
12 (12%)
     Pruritus
9 (9%)
     Rash
11 (11%)
     Skin lesion
5 (5%)
Vascular disorders     Hypertension
6 (6%)
     Hypotension
11 (11%)

  • Discussion of Clinically Important Adverse ReactionsIn the single-arm study (N=99) when decitabine was dosed at 20 mg/m2 intravenous, infused over one hour daily for 5 consecutive days, the highest incidence of Grade 3 or Grade 4 adverse events were neutropenia (37%), thrombocytopenia (24%) and anemia (22%). Seventy-eight percent of patients had dose delays, the median duration of this delay was 7 days and the largest percentage of delays were due to hematologic toxicities. Hematologic toxicities and infections were the most frequent causes of dose delays and discontinuation. Eight patients had fatal events due to infection and/or bleeding (seven of which occurred in the clinical setting of myelosuppression) that were considered at least possibly related to drug treatment. Nineteen of 99 patients permanently discontinued therapy for adverse events.
  • No overall difference in safety was detected between patients > 65 years of age and younger patients in these myelodysplasia trials. No significant gender differences in safety or efficacy were detected. Patients with renal or hepatic dysfunction were not studied. Insufficient numbers of non-white patients were available to draw conclusions in these clinical trials.
  • Serious Adverse Events that occurred in patients receiving decitabine regardless of causality, not previously reported in Tables 1 and 2 include:
  • Blood and Lymphatic System Disorders: myelosuppression, splenomegaly.
  • Cardiac Disorders: myocardial infarction, cardio-respiratory arrest, cardiomyopathy, atrial fibrillation, supraventricular tachycardia.
  • Gastrointestinal Disorders: gingival pain, upper gastrointestinal hemorrhage.
  • General Disorders and Administrative Site Conditions: chest pain, catheter site hemorrhage.
  • Hepatobiliary Disorders: cholecystitis.
  • Infections and Infestations: fungal infection, sepsis, bronchopulmonary aspergillosis, peridiverticular abscess, respiratory tract infection, pseudomonal lung infection, Mycobacterium avium complex infection.
  • Injury, Poisoning and Procedural Complications: post procedural pain, post procedural hemorrhage.
  • Nervous System Disorders: intracranial hemorrhage.
  • Psychiatric Disorders: mental status changes.
  • Renal and Urinary Disorders: renal failure, urethral hemorrhage.
  • Respiratory, Thoracic and Mediastinal Disorders: hemoptysis, lung infiltration, pulmonary embolism, respiratory arrest, pulmonary mass.
  • Allergic Reaction: Hypersensitivity (anaphylactic reaction) to decitabine has been reported in a Phase 2 trial.

Pregnancy Category D [see Warnings and Precautions (5.2)]Decitabine can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of decitabine in pregnant women.
The developmental toxicity of decitabine was examined in mice exposed to single IP (intraperitoneal) injections (0, 0.9 and 3.0 mg/m2, approximately 2% and 7% of the recommended daily clinical dose, respectively) over gestation days 8, 9, 10 or 11. No maternal toxicity was observed but reduced fetal survival was observed after treatment at 3 mg/m2 and decreased fetal weight was observed at both dose levels. The 3 mg/m2 dose elicited characteristic fetal defects for each treatment day, including supernumerary ribs (both dose levels), fused vertebrae and ribs, cleft palate, vertebral defects, hind-limb defects and digital defects of fore- and hind-limbs. In rats given a single IP injection of 2.4, 3.6 or 6 mg/m2 (approximately 5, 8, or 13% the daily recommended clinical dose, respectively) on gestation days 9 to 12, no maternal toxicity was observed. No live fetuses were seen at any dose when decitabine was injected on gestation day 9. A significant decrease in fetal survival and reduced fetal weight at doses greater than 3.6 mg/m2 was seen when decitabine was given on gestation day 10. Increased incidences of vertebral and rib anomalies were seen at all dose levels, and induction of exophthalmia, exencephaly, and cleft palate were observed at 6.0 mg/m2. Increased incidence of foredigit defects was seen in fetuses at doses greater than 3.6 mg/m2. Reduced size and ossification of long bones of the fore-limb and hind-limb were noted at 6.0 mg/m2. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of child bearing potential should be advised to avoid becoming pregnant while taking decitabine.

6.2 Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of decitabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cases of Sweet's Syndrome (acute febrile neutrophilic dermatosis) have been reported.

7 Drug Interactions

Drug interaction studies with decitabine have not been conducted. In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes. In vitro metabolism studies have suggested that decitabine is not a substrate for human liver cytochrome P450 enzymes. As plasma protein binding of decitabine is negligible (<1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.

8.3 Nursing Mothers

It is not known whether decitabine or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from decitabine in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

The safety and effectiveness of decitabine in pediatric patients have not been established.

8.5 Geriatric Use

Of the total number of patients exposed to decitabine in the controlled clinical trial, 61 of 83 patients were age 65 and over, while 21 of 83 patients were age 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

8.6 Renal Impairment

There are no data on the use of decitabine in patients with renal dysfunction; therefore, decitabine should be used with caution in these patients.

8.7 Hepatic Impairment

There are no data on the use of decitabine in patients with hepatic dysfunction; therefore, decitabine should be used with caution in these patients.

10 Overdosage

There is no known antidote for overdosage with decitabine. Higher doses are associated with increased myelosuppression including prolonged neutropenia and thrombocytopenia. Standard supportive measures should be taken in the event of an overdose.

11 Description

Decitabine for Injection, for intravenous infusion only, contains decitabine (5-aza-2'-deoxycitidine), an analogue of the natural nucleoside 2'-deoxycytidine. Decitabine is a fine, white to almost white powder with the molecular formula of C8H12N4O4 and a molecular weight of 228.21. Its chemical name is 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one and it has the following structural formula:
Decitabine is slightly soluble in ethanol/water (50/50), methanol/water (50/50) and methanol; sparingly soluble in water and soluble in dimethylsulfoxide (DMSO).
Decitabine for Injection is a white to almost white sterile lyophilized powder supplied in a clear colorless glass vial. Each single-dose glass vial contains 50 mg decitabine, 68 mg monobasic potassium phosphate (potassium dihydrogen phosphate) and 11.6 mg sodium hydroxide.

12.1 Mechanism Of Action

Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine.

12.2 Pharmacodynamics

Decitabine has been shown to induce hypomethylation both in vitro and in vivo. However, there have been no studies of decitabine-induced hypomethylation and pharmacokinetic parameters.

12.3 Pharmacokinetics

Pharmacokinetic parameters were evaluated in patients. Eleven patients received 20 mg/m2 infused over 1 hour intravenously (treatment Option 2). Fourteen patients received 15 mg/m2 infused over 3 hours (treatment Option 1). PK parameters are shown in Table 3. Plasma concentration-time profiles after discontinuation of infusion showed a biexponential decline. The CL of decitabine was higher following treatment Option 2. Upon repeat doses there was no systemic accumulation of decitabine or any changes in PK parameters. Population PK analysis (N=35) showed that the cumulative AUC per cycle for treatment Option 2 was 2.3-fold lower than the cumulative AUC per cycle following treatment Option 1.
Table 3 Mean (CV% or 95% CI) Pharmacokinetic Parameters of Decitabine
* N=14, **N=11, ***N=35 Cumulative AUC per cycle
DoseCmax(ng/mL)AUC0-∞
(ng·h/mL)T½
(h)CL (L/h/m2)AUCCumulative
***
(ng·h/mL)15 mg/m2 3-hr infusion every 8 hours for 3 days (Option 1)*73.8(66)
163(62)
0.62(49)
125(53)
1332(1010 to 1730)
20 mg/m2 1-hr infusion daily for 5 days (Option 2)**147(49)
115(43)
0.54(43)
210(47)
570(470 to 700)
The exact route of elimination and metabolic fate of decitabine is not known in humans. One of the pathways of elimination of decitabine appears to be deamination by cytidine deaminase found principally in the liver but also in granulocytes, intestinal epithelium and whole blood.

13.1 Carcinogenesis, Mutagenesis And Impairment Of Fertility

Carcinogenicity studies with decitabine have not been conducted.
The mutagenic potential of decitabine was tested in several in vitro and in vivo systems. Decitabine increased mutation frequency in L5178Y mouse lymphoma cells, and mutations were produced in an Escherichia coli lac-I transgene in colonic DNA of decitabine-treated mice. Decitabine caused chromosomal rearrangements in larvae of fruit flies.
The effect of decitabine on postnatal development and reproductive capacity was evaluated in mice administered a single 3 mg/m2 IP injection (approximately 7% the recommended daily clinical dose) on day 10 of gestation. Body weights of males and females exposed in utero to decitabine were significantly reduced relative to controls at all postnatal time points. No consistent effect on fertility was seen when female mice exposed in utero were mated to untreated males. Untreated females mated to males exposed in utero showed decreased fertility at 3 and 5 months of age (36% and 0% pregnancy rate, respectively). In male mice given IP injections of 0.15, 0.3 or 0.45 mg/m2 decitabine (approximately 0.3% to 1% the recommended clinical dose) 3 times a week for 7 weeks, decitabine did not affect survival, body weight gain or hematological measures (hemoglobin and WBC counts). Testes weights were reduced, abnormal histology was observed and significant decreases in sperm number were found at doses ≥ 0.3 mg/m2. In females mated to males dosed with ≥ 0.3 mg/m2 decitabine, pregnancy rate was reduced and preimplantation loss was significantly increased.

14.1 Controlled Trial

  • A randomized open-label, multicenter, controlled trial evaluated 170 adult patients with myelodysplastic syndromes (MDS) meeting French-American-British (FAB) classification criteria and International Prognostic Scoring System (IPSS) High-Risk, Intermediate-2 and Intermediate-1 prognostic scores. Eighty-nine patients were randomized to decitabine therapy plus supportive care (only 83 received decitabine), and 81 to Supportive Care (SC) alone. Patients with Acute Myeloid Leukemia (AML) were not intended to be included. Of the 170 patients included in the study, independent review (adjudicated diagnosis) found that 12 patients (9 in the decitabine arm and 3 in the SC arm) had the diagnosis of AML at baseline. Baseline demographics and other patient characteristics in the Intent-to-Treat (ITT) population were similar between the 2 groups, as shown in Table 4.
  • Table 4 Baseline Demographics and Other Patient Characteristics (ITT)
  • Demographic or Other Patient CharacteristicDecitabineN = 89SupportiveCareN= 81Age (years)Mean (±SD)
  • 69±10
  • 67±10
  • Median (IQR)
  • 70 (65 to 76)
  • 70 (62 to 74)
  • (Range: min-max)
  • (31 to 85)
  • (30 to 82)
  • Gender n (%)Male
  • 59 (66)
  • 57 (70)
  • Female
  • 30 (34)
  • 24 (30)
  • Race n (%)White
  • 83 (93)
  • 76 (94)
  • Black
  • 4 (4)
  • 2 (2)
  • Other
  • 2 (2)
  • 3 (4)
  • Weeks Since MDS DiagnosisMean (±SD)
  • 86±131
  • 77±119
  • Median (IQR)
  • 29 (10 to 87)
  • 35 (7 to 98)
  • (Range: min-max)
  • (2 to 667)
  • (2 to 865)
  • Previous MDS Therapy n (%)Yes
  • 27 (30)
  • 19 (23)
  • No
  • 62 (70)
  • 62 (77)
  • RBC Transfusion Status n (%)Independent
  • 23 (26)
  • 27 (33)
  • Dependent
  • 66 (74)
  • 54 (67)
  • Platelet Transfusion Status n (%)IndependentDependent
  • 69 (78)20 (22)
  • 62 (77)19 (23)
  • IPSS Classification n (%)Intermediate-1
  • 28 (31)
  • 24 (30)
  • Intermediate-2
  • 38 (43)
  • 36 (44)
  • High Risk
  • 23 (26)
  • 21 (26)
  • FAB Classification n (%)RA
  • 12 (13)
  • 12 (15)
  • RARS
  • 7 (8)
  • 4 (5)
  • RAEB
  • 47 (53)
  • 43 (53)
  • RAEB-t
  • 17 (19)
  • 14 (17)
  • CMML
  • 6 (7)
  • 8 (10)
  • Patients randomized to the decitabine arm received decitabine intravenously infused at a dose of 15 mg/m2 over a 3-hour period, every 8 hours, for 3 consecutive days. This cycle was repeated every 6 weeks, depending on the patient's clinical response and toxicity. Supportive care consisted of blood and blood product transfusions, prophylactic antibiotics, and hematopoietic growth factors. The study endpoints were overall response rate (complete response + partial response) and time to AML or death. Responses were classified using the MDS International Working Group (IWG) criteria; patients were required to be RBC and platelet transfusion independent during the time of response. Response criteria are given in Table 5:
  • Table 5 Response Criteria for Phase 3 Trial**Cheson BD, Bennett JM, et al. Report of an International Working Group to Standardize Response Criteria for MDS. Blood. 2000; 96:3671-3674.
  • Complete Response (CR)≥ 8 weeksBone MarrowOn repeat aspirates:< 5% myeloblasts
  • No dysplastic changes
  • Peripheral BloodIn all samples during response:Hgb > 11 g/dL (no transfusions or erythropoietin
  • ANC ≥ 1500/μL (no growth factor)
  • Platelets ≥ 100,000/μL (no thrombopoietic agent)
  • No blasts and no dysplasia
  • Partial Response (PR)≥ 8 weeksBone MarrowOn repeat aspirates:≥ 50% decrease in blasts over pretreatment valuesOR
  • Improvement to a less advanced MDS FAB classification
  • Peripheral BloodSame as for CRThe overall response rate (CR+PR) in the ITT population was 17% in decitabine-treated patients and 0% in the SC group (p<0.001). (See Table 6) The overall response rate was 21% (12/56) in decitabine-treated patients considered evaluable for response (i.e., those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment). The median duration of response (range) for patients who responded to decitabine was 288 days (116 to 388) and median time to response (range) was 93 days (55 to 272). All but one of the decitabine-treated patients who responded did so by the fourth cycle. Benefit was seen in an additional 13% of decitabine-treated patients who had hematologic improvement, defined as a response less than PR lasting at least 8 weeks, compared to 7% of SC patients. Decitabine treatment did not significantly delay the median time to AML or death versus supportive care.
  • Table 6 Analysis of Response (ITT)
  • **p-value <0.001 from two-sided Fisher's Exact Test comparing Decitabine vs. Supportive Care.
  • †In the statistical analysis plan, a p-value of ≤ 0.024 was required to achieve statistical significance.
  • ParameterDecitabineN=89Supportive CareN=81Overall Response Rate (CR+PR)†     Complete Response (CR)     Partial Response (PR)
  • 15 (17%)**8 (9%)7 (8%)
  • 0 (0%)0 (0%)0 (0%)
  • Duration of ResponseMedian time to (CR+PR)     response - Days (range)Median Duration of (CR+PR)     response - Days (range)
  • 93 (55 to 272)288 (116 to 388)
  • NANA
  • All patients with a CR or PR were RBC and platelet transfusion independent in the absence of growth factors.
  • Responses occurred in patients with an adjudicated baseline diagnosis of AML.

14.2 Single-Arm Studies

Three open-label, single-arm, multicenter studies were conducted to evaluate the safety and efficacy of decitabine in MDS patients with any of the FAB subtypes. In one study conducted in North America, 99 patients with IPSS Intermediate-1, Intermediate-2, or high risk prognostic scores received decitabine by intravenous infusion at a dose of 20 mg/m2 IV over 1-hour daily, on days 1 to 5 of week 1 every 4 weeks (1 cycle). The results were consistent with the results of the controlled trial and summarized in Table 8.
Table 7 Baseline Demographics and Other Patient Characteristics (ITT)
Demographic or Other Patient CharacteristicDecitabineN = 99Age (years)Mean (±SD)
71±9
Median (Range: min-max)
72 (34 to 87)
Gender n (%)Male
71 (72)
Female
28 (28)
Race n (%)White
86 (87)
Black
6 (6)
Asian
4 (4)
Other
3 (3)
Days From MDS Diagnosis to First DoseMean (±SD) Median (Range: min-max)
444±626154 (7 to 3079)
Previous MDS Therapy n (%)Yes
27 (27)
No
72 (73)
RBC Transfusion Status n (%) Independent
33 (33)
Dependent
66 (67)
Platelet Transfusion Status n (%)Independent
84 (85)
Dependent
15 (15)
IPSS Classification n (%)Low Risk
1 (1)
Intermediate–1
52 (53)
Intermediate–2High Risk
23 (23)23 (23)
FAB Classification n (%)RARARSRAEBRAEB-tCMML
20 (20)17 (17)45 (45)6 (6)11 (11)
Table 8 Analysis of Response (ITT)*+ indicates censored observation
* Cheson BD, Bennett JM, et al. Report of an International Working Group to Standardize Response Criteria for MDS. Blood. 2000; 96:3671-3674.
ParameterDecitabineN=99Overall Response Rate (CR+PR)     Complete Response (CR)     Partial Response (PR)
16 (16%)15 (15%)1 (1%)
Duration of ResponseMedian time to (CR+PR) response – Days     (range)Median Duration of (CR+PR) response –     Days (range)
162 (50 to 267)443 (72 to 722+)

15 References

  • NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
  • OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
  • American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: Am J Health-Syst Pharm. 2006;63:1172-1193.
  • Polovich M., White JM, Kelleher LO (eds). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.) 2005. Pittsburgh, PA: Oncology Nursing Society.

16 How Supplied/Storage And Handling

Decitabine for Injection is supplied as follows:
NDCDecitabine for InjectionPackage Factor25021-231-20
50 mg Single-Dose Vial
1 vial per carton

Storage And Handling

Storage ConditionsStore at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.]
Discard unused portion.Keep this and all medications out of the reach of children.Sterile, Nonpyrogenic, Preservative-free.The container closure is not made with natural rubber latex.

17.1 Instructions For Patients

Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with decitabine and for 1 month afterwards, and to use effective contraception during this time, [see Warnings and Precautions (5.3)].Men should be advised not to father a child while receiving treatment with decitabine, and for 2 months afterwards. During these times, men with female partners of childbearing potential should use effective contraception [see Warnings and Precautions (5.4) and Nonclinical Toxicology (13.1)].
Patients should be advised to monitor and report any symptoms of neutropenia, thrombocytopenia, or fever to their physician as soon as possible [see Warnings and Precautions (5.1)].SAGENT®Mfd. for SAGENT PharmaceuticalsSchaumburg, IL 60195 (USA)Made in China©2017 Sagent Pharmaceuticals, Inc.
September 2017
SAGENT Pharmaceuticals®

* Please review the disclaimer below.